Clinical Trial Search

Primary: Number of Participants That Experienced a Dose Limiting Toxicity (DLT) — 0; 0; 0; 0 participants

Primary: Number of Subjects With a Varicella Vaccine Response — 1 Participants

Primary: Mean Ratings on Clinical Opiate Withdrawal Scale (COWS) Measure of Withdrawal During Double-blind Taper (7-days) and Post-taper (7-days) Period. — 7.79; 8.41; 8.28; 6.16…

Primary: Change From Baseline at Month 3 in cCK18/M30 — 293.5; 257.5; 288.5; 285.0 U/L

Primary: Change From Baseline in the Percentage of Total White Blood Cell That Were Eosinophils at 48 Hours — 82.11 percent of white blood cells

Primary: Forced Expiratory Volume in 1 Second (FEV1) — 2.31; 2.25 liters

Primary: Regimen-Related Toxicities — 21; 10; 8; 16 Toxicities

Primary: Regulatory T Cells (Tregs)/Total CD4+ Cells at Day 30 Post-HCT — 23.8 percentage of CD4+Tregs

Primary: Transplant Related Mortality (TRM) — 8.5 percentage of participants

Primary: Clinical Response Rate Following Induction Chemotherapy — 10; 20; 9 Participants

Primary: Response to Neoadjuvant Therapy by Therapy Arms: Clinical Response Rates (CR + PR + SD) — 4; 7; 14; 11 Participants

Primary: Number of Patients Able to Complete 6 Cycles of Treatment. — 17 Participants

Primary: Number of Patients to Mobilize ≥5 x 10^6 CD34 Cells/kg Autologous PBSC (Efficacy) — 17 Participants

Primary: Phase 1: Maximum Tolerated Dose (MTD) — 1; 0; 1; 1 participants

Primary: Production of Anti-Retinal Pigment Epithelium (RPE) or Anti-retinal Antibody Formation in Neovascular ("Wet") Age-related Macular Degeneration Patients Compared to…